Dan Baker says he always harps on about joints; in particular, the fact that they don’t tend to heal very well.
It’s a key driver of his, and his company’s approach to combating rheumatoid arthritis, a debilitating disease that affects up to 20 million people worldwide.
Dr Baker joined Remicade (infliximab) developer Centocor at the time the blockbuster anti-TNF biologic was being developed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze